If you put the recent 'recommendation' aside, have a look at EVGs annoucements over the past few months. They have been screaming for attention, the pattern is already out of whack and just playing catch up.
Funnily enough, many companies run ahead of their mystical NPVs based on exploration upside and ambiguity over how to value them. Here you have EVG who have very cleary articulated their case for value and were sitting at a third of it a week ago, being only a few months out from arguably hitting it; and that after several very hard years at work with most of the startup risk already dealt with.
There is substantial upside with EVG on its exploration alone. As a subscriber to DandD, I dont think that their aim is to churn out overnight winners, so much as find clearly undervalued prospects and highlight them to the market.
I do agree that it would be good to see the Doctor have some skin in the game, but this is their call. I guess you could also consider what it would mean for his image if he was to send out emails like "hey guys, just exited for $0.33 try and get as good a price as me, dont worry if you can't, whats a few dollars between subscribers and editors".
No skin is a safe policy on a widely read publication I think.
Cheers,
SF
EVG Price at posting:
19.0¢ Sentiment: Buy Disclosure: Held
